**Xilio Therapeutics Inc. Receives Nasdaq Listing Transfer, Granted Additional Time to Regain Compliance** Xilio Therapeutics Inc. announced that its common stock will be transferred from the Nasdaq Global Select Market to the Nasdaq Capital Market, effective October 6, 2025. The move follows the company's failure to meet the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1). The transfer grants Xilio an additional 180-day grace period, until March 30, 2026, to regain compliance. To do so, the company's stock must close at $1.00 or above for at least 10 consecutive business days. Xilio's shares will continue to trade under the symbol "XLO" as the company evaluates options to address the issue.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xilio Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-229231), on October 03, 2025, and is solely responsible for the information contained therein.